New Data on Endevica Bio’s Lead Compound, TCMCB07, Published in “ACS Pharmacology & Translational Science” Suggest a Platform Approach for Producing Drug-Like Peptides

Paper Demonstrates Essential Properties of TCMCB07 and Its Potential Ability to Treat Cachexia

COLUMBIA, Mo.--(BUSINESS WIRE)--Researchers affiliated with Endevica Bio (formerly known as Tensive Controls Inc.), a company developing first-in-class peptide drug candidates with better safety and efficacy properties, published new data on Endevica’s lead compound, TCMCB07, in the journal ACS Pharmacology & Translational Science. The research describes the unique mechanisms and properties of the drug, specifically in the treatment of cachexia, and the potential for producing a platform for drug-like peptides based on this evidence.

The article, “Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-Like Peptides,” was authored by the founder and Chief Scientific Officer of Endevica, Dr. Kenneth A. Gruber, and his colleagues at the University of Missouri and Auburn University.

“Peptides have held promise for treating a wide range of diseases that have no viable treatment option, such as cachexia, but certain properties have historically inhibited their development as drugs,” said Dr. Gruber. “Our research showed that TCMCB07 crosses the blood brain barrier to act on the melanocortin system for the treatment of cachexia. Importantly, we also saw evidence that our technology can be used to create other drug-like peptides using a similar approach.”

“This research is important as we finalize our IND-enabling studies and prepare for clinical trials of TCMCB07 in cachexia,” said Russ Potterfield, Executive Chairman of Endevica Bio. “Further it showcases our expertise in peptide drug delivery as we continue to build out our pipeline and expand into sister indications.”

About Endevica Bio

Endevica Bio was formed to create first-in-class peptide drug candidates with better safety and efficacy properties than other drugs in the same class. Endevica’s technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to perform with improved half-life, oral activity, and the ability to cross the blood-brain barrier. Endevica’s initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.